What other stocks do shareholders of Vodis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vodis Pharmaceuticals investors own include Allena Pharmaceuticals (ALNA) , Ampliphi Biosciences (APHB) , Arbutus Biopharma (ABUS) , Aurora Cannabis (ACBFF) , AcelRx Pharmaceuticals (ACRX) , Aldeyra Therapeutics (ALDX) , Apellis Pharmaceuticals (APLS) , Aquinox Pharmaceuticals (AQXP) .

How do I buy shares of Vodis Pharmaceuticals?

Shares of VP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

CNSX:VP

Vodis Pharmaceuticals (VP) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free VP Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 51,582 shs
Average Volume: 1,714 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Vodis Pharmaceuticals alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Vodis Pharmaceuticals Stock (CNSX:VP)

Vodis Pharmaceuticals Inc. operates as an application stage company for producing medical marijuana. It operates in Canada and the United States. The company is based in Delta, Canada.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

VP Stock News Headlines

March 27, 2024 | tmcnet.com

COVETRUS® TRANSFORMS PRESCRIPTION MANAGEMENT FOR VETERINARY PRACTICES WITH INTRODUCTION OF vRxPro™

March 22, 2024 | msn.com

States' drug pricing boards off to a slow start

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 25, 2024 | msn.com

Verrica Pharmaceuticals Set to Discuss Q4 and Full-Year 2023 Financial Results in Upcoming Conference Call

February 7, 2024 | markets.businessinsider.com

Abivax appoints Ana Sharma as Vice President, Global Head of Quality

January 24, 2024 | markets.businessinsider.com

Medicines360 Appoints Lisa David as Chair of the Board of Directors, Strengthening its Commitment to Women’s Health

December 14, 2023 | msn.com

Dr Reddy's becomes sole Indian pharma player to make it to Dow Jones Sustainability World Index 2023

December 7, 2023 | msn.com

Biden warns Big Pharma: Make your drugs cheaper or the US government will override your patents

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

December 7, 2023 | abcnews.go.com

The White House is threatening the patents of high-priced drugs developed with taxpayer dollars

December 1, 2023 | msn.com

Amneal Pharma in pact with Strides to launch generic Vascepa

November 6, 2023 | markets.businessinsider.com

Anavex Life Sciences Appoints Senior VP of Regulatory Affairs

October 14, 2023 | foxnews.com

Xpeng's vice president suspended amid corruption investigation in supply chain management

October 9, 2023 | marketwatch.com

Lexicon Pharmaceuticals Up 20% on Express Scripts Designation for Inpefa Heart Drug

October 4, 2023 | markets.businessinsider.com

Strengthening of vertical integration: Exyte completes acquisition of pure media specialist Intega

September 19, 2023 | newsweek.com

Vice President

August 28, 2023 | usatoday.com

Republican voters want Donald Trump. And his vice president? How about more Trump?

August 22, 2023 | news.yahoo.com

Teva Pharmaceuticals to pay $225M fine to settle price-fixing charges

August 1, 2023 | msn.com

Vertex Pharmaceuticals (VRTX) Q2 2023 Earnings Call Transcript

May 29, 2023 | news.yahoo.com

What has Kamala Harris done as vice president?

March 31, 2023 | nytimes.com

Vice President Kamala Harris: Latest News

February 1, 2023 | yahoo.com

Ionis announces GSK has advanced bepirovirsen into Phase 3 development

January 27, 2023 | yahoo.com

ZyVersa Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4)

January 12, 2023 | marketwatch.com

The way Medicare will negotiate down prescription drug prices takes shape

January 10, 2023 | msn.com

Glenmark Pharmaceuticals launches congestive heart failure injection in United States

January 7, 2023 | msn.com

More families facing price shocks for lifesaving children's medications

January 6, 2023 | cnn.com

FDA to review preventative option for RSV in infants, developers say

See More Headlines

Receive VP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vodis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: CNSX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: CNSX:VP
CUSIP: N/A
CIK: N/A
Web: vodis.ca
Phone: 778-990-8985
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Brian R. Gusko (Age 52)
Advisor
Mr. Mark Lotz B.B.A.
C.A., CPA, Interim CEO, CFO & Director

Key Competitors

View All Competitors

VP Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Vodis Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vodis Pharmaceuticals investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP).
How do I buy shares of Vodis Pharmaceuticals?: Shares of VP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (CNSX:VP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Vodis Pharmaceuticals (VP) Stock Price, News & Analysis

About Vodis Pharmaceuticals Stock (CNSX:VP)

VP Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

VP Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info